MBBS FRACP PhD
A/Prof Tarek Meniawy is a Medical Oncologist with a special interest in the management of gynaecological cancers, melanoma of the skin, as well as cancer immunotherapy and clinical trials. He is accredited at St John of God Subiaco Hospital and also holds Consultant appointments at Sir Charles Gairdner Hospital and the King Edward Memorial Hospital. He is also a Clinical Associated Professor at the University of Western Australia and Edith Cowan University.
Tarek completed his medical degree at Cairo University, before undertaking postgraduate physician training at the Princess Alexandra Hospital in Brisbane. He then undertook further training in Medical Oncology at Royal Perth Hospital and Sir Charles Gairdner Hospital, before being awarded the Fellowship of the Royal Australasian College of Physicians in 2011. He has also been awarded a Doctor of Philosophy (PhD) degree by the University of Western Australia, where he studied the effects of anti-cancer therapies on the immune system.
Dr Meniawy has a keen interest in teaching and research, particularly in the field of cancer immunology and immunotherapy. He is actively involved in clinical trials, acting as a Principal Investigator or co-investigator on more than 20 active studies, including early trials of novel targeted therapies and immunotherapies in different tumour types, large multi-national trials in gynaecological cancers, melanoma and immunotherapy, as well as grant-funded, investigator-initiated research. He is a member of the WA Gynaecological Cancer Service as well as the WA Kirkbride Melanoma Advisory Service. He is also a member of several national and international professional organisations, including the American Society of Clinical Oncology, the International Gynaecological Cancer Society, the Medical Oncology Group of Australia, and the Clinical Oncology Society of Australia. He is an active member of the Australia and New Zealand Gynaecological Oncology Group (ANZGOG) where he has a number of leadership roles. His work was published in a number of original articles in peer-reviewed journals, book chapters and conference papers, and has presented regularly at local, national and international conferences.
- 2016 - Doctor of Philosophy (PhD) – University of Western Australia
- 2011 - Fellow of the Royal Australasian College of Physicians (Medical Oncology)
- 2000 - Bachelor of Medicine, Bachelor of Surgery – Cairo University (MBBS)
- Royal Australasian College of Physicians (RACP)
- American Society of Clinical Oncology (ASCO)
- Australia and New Zealand Gynaecological Oncology Group (ANZGOG)
- International Gynaecological Cancer Society (IGCS)
- WA Gynaecological Cancer Service (WAGCS)
- Medical Oncology Group of Australia (MOGA)
- St John of God Subiaco Hospital – Accredited physician (Medical Oncologist)
- Sir Charles Gairdner Hospital – Consultant Medical Oncologist
- Linear Clinical Research - Consultant Medical Oncologist
- King Edward Memorial Hospital – Visiting Medical Oncologist
Peer reviewed journal articles
McEvoy AC, Calapre L, Pereira MR, Giardina T, Robinson C, Khattak MA, Meniawy TM, Pritchard AL, Hayward NK, Amanuel mB, Millward M, Ziman M, Gray ES. Sensitive droplet digital PCR method for detection of TERT promoter mutations in cell free DNA from patients with metastatic melanoma. Oncotarget. 2017 Aug; https://doi.org/10.18632/oncotarget.20354.
Aya-Bonilla C, AG M, Freeman J, Lomme C, Khattak M, Meniawy T, et al. Isolation and detection of circulating tumour cells from metastatic melanoma patients using a slanted spiral microfluidic device. Oncotarget. 2017; 8:67355-67368. https://doi.org/10.18632/oncotarget.18641.
Coghlan, E., Meniawy, T. M., Munro, A., Bulsara, M., Stewart, C. J., Tan, A., … Cohen, P. A. (2017). Prognostic Role of Histological Tumor Regression in Patients Receiving Neoadjuvant Chemotherapy for High-Grade Serous Tubo-ovarian Carcinoma. International Journal of Gynecological Cancer, 27(4), 708–713.
Meniawy TM, Lake RA, McDonnell A, Millward M, Nowak AK. PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors. Lung Cancer. 2016 Jan; 93: 9–16
Brims F, Meniawy TM, Duffus I, Segal A, Creaney J, Lake RA, et al. A novel clinical prediction model for prognosis in newly diagnosed malignant pleural mesothelioma using decision tree analysis. Journal of Thoracic Oncology. 2016. http://doi.org/10.1016/j.jtho.2015.12.108.
Gray ES, Rizos M, Reid AL, Boyd SC, Pereira MR, Lo J, Tembe V, Freeman J, Lee JHJ, Scolyer RA, Siew K, Cooper A, Khattak MA, Meniawy TM, et al. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget. 2015; 6(39): 42008—42018.
Meniawy TM, Creaney J, Lake RA, Nowak AK. Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma. Br J Cancer. 2013 Oct 1;109(7):1813-20.
Meniawy TM, Creaney J, Lake RA, Nowak AK. Reply to Comment on 'Existing prognostic models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma'. Br J Cancer. 2014 Apr 8.
Creaney J, Dick IM, Meniawy TM, Leong SL, Leon JS, Demelker Y, et al. Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma. Thorax. 2014 Jul 18. DOI: 10.1136/thoraxjnl-2014-205205.
Meniawy TM, Nowak AK, Lake RA. Effect of chemotherapy on the tumor microenvironment and anti-tumor immunity. In: Keisari Y, editor. In situ Tumor Ablation and its effect on the tumor microenvironment and anti-tumor immunity. Netherlands: Springer; 2012.
Meniawy TM, Robinson BWS. Malignant Mesothelioma. In: Spiro SG, Silvestri GA, Agusti A, editors. Clinical Respiratory Medicine. 4th ed. Philadelphia: Elsevier; 2012.
Meniawy T, Richardson G, Townsend A, Desai J, Gan H, Friedlander M, Horvath L, Jameson MB, Sandhu S, Wu Z, Qin Z, Kang. Preliminary results from a subset of patients (pts) with advanced ovarian cancer (OC) in a dose-escalation/expansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb). In: Proceedings of the 2017 ESMO Annual meeting. Annals of Oncology 28(suppl_5) · September 2017.
M Friedlander, T Meniawy, B Markman, LR. Mileshkin, PR. Harnett, M Millward, J Lundy, AE. Freimund, C Norris, S Mu, J Wu, VE. Paton, L Wang, B Gao. A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors. In: Proceedings of the 2017 ASCO Annual meeting; 2017 Jun 3-6; Chicago, IL: J Clin Oncol 35, 2017 (suppl; abstr 3013).
Siu, L. L., Steeghs, N., Meniawy, T., et al. (2017) Preliminary results of a phase I/IIa study of BMS-986156 (glucocorticoid-induced tumor necrosis factor receptor–related gene [GITR] agonist), alone and in combination with nivolumab in pts with advanced solid tumors. In: Proceedings of the 2017 ASCO Annual meeting; 2017 Jun 3-6; Chicago, IL: J Clin Oncol. 35: 104-104.
Meniawy TM, McCoy MJ, Coghlan E, Anyaegbu CC, Austin SJ, et al. Higher PD-L1 expression predicts poor prognosis in patients with tubo-ovarian high-grade serous carcinoma treated with neoadjuvant chemotherapy. In Proceedings of the ANZGOG Annual Scientific Meeting; 2017 Mar 29-Apr 1 ; Melbourne; Victoria.
Coghlan E, Meniawy TM, Munro A, Bulsara M, Stewart CJR, et al. Prognostic role of histologic tumor regression in patients receiving neoadjuvant chemotherapy for high-grade serous tubo-ovarian carcinoma. In Proceedings of the 2017 ANZGOG Annual Scientific meeting; 2016 Mar 29-Apr 1; Melbourne; Victoria.
J Lickliter, H Gan, T Meniawy, J Yang, L Wang, L Luo, M Millward. A phase I dose-escalation study of BGB-290, a novel PARP1/2 selective inhibitor in patients with advanced solid tumors. In: Proceedings of the 2016 ASCO Annual meeting; 2016 Jun 3-7; Chicago, IL: J Clin Oncol 34, 2016 (suppl; abstr e17049).
SP Blagden, H Gabra, A L. Hamilton, S S. Wong, A Michael, L R. Mileshkin, M Hall, J Goh, A S Lisyanskaya, M DeSilvio, D Habr, S Gainer, P Gopalakrishna, T Meniawy. Phase I/II dose-escalation and expansion study of afuresertib + carboplatin and paclitaxel in recurrent ovarian cancer. In: Proceedings of the 2016 ASCO Annual meeting; 2016 Jun 3-7; Chicago, IL: J Clin Oncol 34, 2016 (suppl; abstr 2551).
J Desai, B Markman, S Kaur Sandhu, HK Gan, M Friedlander, B Tran, T Meniawy, V Boolell, D Colyer, C Norris, M Ameratunga, J Yang, K Li, L Wang, L Luo, Z Qin, M Millward. A phase I dose-escalation study of BGB-A317, an anti-programmed death-1 (PD-1) mAb in patients with advanced solid tumors. In: Proceedings of the 2016 ASCO Annual meeting; 2016 Jun 3-7; Chicago, IL: J Clin Oncol 34, 2016 (suppl; abstr 3066).
J Lickliter, H Gan, T Meniawy, J Yang, L Wang, L
Luo, M Millward. Phase 1 study of a novel PARP1/2 selective inhibitor, BGB-290 [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr PR11.
Meniawy TM, Lake RA, McDonnell AM, Millward M, Nowak AK. Up regulation of PD-L1 on peripheral blood CD3+ T cells predicts poor prognosis in patients with non-small cell lung cancer (NSCLC) treated with epidermal growth factor receptor (EGFR) inhibitors. Proceedings of the 18th ECCO - 40th ESMO European Cancer Congress; 2015, 25-29 Sept; Vienna, Austria. European Journal of Cancer. Vol. 51:S47–S47.
Blagden S, Hamilton A, Mileshkin L, Hall M, Meniawy T, Wong S, et al. Afuresertib (GSK2110183), an oral AKT kinase inhibitor, in combination with carboplatin and paclitaxel in recurrent ovarian cancer. Proceedings of the 26th EORTC–NCI–AACR Symposium on Molecular Targets and Cancer Therapeutics; 2014, 18-21 Nov; Barcelona, Spain. European Journal of Cancer. 2014;50(S6).
Brims F, Meniawy T, Creaney J, Lake R, Nowak A. Routinely Collected Clinical and Laboratory Data Can Reliably Predict Longer Survival in Malignant Pleural Mesothelioma. Proceeding of the Thoracic Society of Australia & New Zealand Annual Scientific Meeting; 2014, 4-9 Apr; Adelaide, Australia. Respirology. 2014 Apr;19(S2):16-16.
Meniawy TM, Lake RA, Nowak AK. The effects of epidermal growth factor (EGFR) receptor inhibitors on the immune system in patients with advanced non-small cell lung cancer (NSCLC). Proceedings of the 15th World Conference on Lung Cancer; 2013 27-31 Oct; Sydney, Australia. J Thorac Oncol. 2013 Nov;8(2):S374.
Meniawy TM, Creaney J, Lake RA, Nowak AK. EORTC and CALGB prognostic models, but not neutrophil-to-lymphocyte ratio, are prognostic in unselected patients with newly diagnosed malignant mesothelioma. Proceedings of the 15th World Conference on Lung Cancer Sydney, Australia. J Thorac Oncol. 2013;8(2):S935.
Meniawy TM, Davidson A. Early predictive value post chemotherapy of metabolic response assessment using FDG-PET in NSCLC. Proceedings of the Australian Lung Cancer Conference; 2010 7-9 Oct; Melbourne, Australia.
Meniawy TM, Davidson A. Early predictive value post chemotherapy of metabolic response assessment using fluorodeoxyglucose positron emission tomography (FDG-PET) in Non Small Cell Lung Cancer. Proceedings of the 2nd European Lung Cancer Conference; 2010 28 Apr-1 May; Geneva, Switzerland. J Thorac Oncol. 2010 May;5(5):S63.